An open label, phase 1/2 safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive

Administered By

Duke Cancer Institute

Contributors

Berry, William Rosser Principal Investigator

Start/End

October 1, 2014 - December 31, 2017